This article is my personal perspective as a patient, and it is educational, not medical advice. The Vitamin D3 Anti-Inflammatory Regimen involves high doses and can cause harm, mainly through raised calcium, if the wrong person takes the wrong dose without monitoring. Please read it alongside a qualified clinician and your own baseline blood tests.
Two questions land in my inbox almost every week, from people in every corner of the planet.
If this regimen helps so many of us, why has nobody run a proper study?
And why, when I raise it, does my doctor look at me as though I have lost my mind?
I want to answer both honestly. Not with a conspiracy, because this is not one, but with the uncomfortable mechanics of how medicine actually gets studied, funded and taught. Once you see those mechanics, the silence stops being mysterious. It starts being predictable. And that, in a strange way, is the most reassuring part.
This is not a conspiracy. It is incentives.
Let me kill the conspiracy idea first, because it helps nobody.
Vitamin D3 is an endogenous molecule. Your own skin makes it from sunlight. It is sold in every pharmacy and supermarket on earth for a few dollars. Nobody owns it. Nobody can patent it. And that single fact explains most of the silence.
A pharmaceutical company funds a trial because, at the end, it hopes to sell a protected product and recover the cost many times over. A large trial costs millions. For a cheap, unpatentable vitamin, there is no product to protect and no return to recover. So there is no commercial reason for a drug company to spend that money. That is not villainy. It is simple arithmetic, and it is the same reason so many cheap, generic and natural interventions never get the big studies they might deserve.
The problem is that when industry will not pay, almost nobody else can either.
Why there is still no large trial
When people assume a trial would be easy, they underestimate how much has to line up. Here is what stands in the way, from my vantage point as a patient who has watched this closely for over a decade.
1. There is no one to fund it
With no commercial sponsor, a trial depends on public grants, universities or small disease charities. Those pots are tiny, fiercely contested, and rarely flow toward an unpatentable vitamin for a rare condition. The money that drives most of the research you read about simply is not there for this.
2. Recruitment is brutally hard
Cluster headache is rare. Finding enough patients who fit strict trial criteria, in the right place, at the right time, willing to be randomised, is a mountain in itself. I understand that an attempt was made during the COVID years, pursued as I understand it by Dr Mark Burish, and that it could not recruit the numbers it needed to proceed. A pandemic that shut clinics and froze travel was about the worst possible moment to try. That failure was not a verdict on the regimen. It was a verdict on how fragile recruitment is for a rare disease at the worst of times.
3. The washout problem
To test a preventive cleanly, trialists often want patients to come off their existing medications first, so the picture is not muddied. Think about what that asks of a cluster headache patient. You are asking someone who has finally wrestled one of the most painful conditions known to medicine under some control to deliberately stop what is working and risk the attacks returning, for the sake of a study. Many people will not do it, and frankly I do not blame them. That alone sinks a lot of designs before they start.
4. The ethics are genuinely hard
Randomising sufferers of an agonising condition to a placebo raises real ethical questions. Ethics committees exist to protect patients, and they should. But every safeguard adds time, cost and complexity, and for a condition this severe the bar is high and the debate is legitimate.
5. The condition itself fights the study design
Cluster headache is often episodic. Cycles arrive and then lift on their own. Episodic and chronic forms behave differently. Spontaneous remission can look like a treatment effect, and a treatment effect can be dismissed as spontaneous remission. To separate signal from noise you need long timelines, careful design and large numbers, which loops straight back to funding and recruitment.
6. The regimen is not one simple pill
This is not a single dose you can drop into a neat randomised box. There is a loading phase and a maintenance phase. There are cofactors. There are blood level targets and ongoing monitoring of 25(OH)D, calcium and PTH. Designing a clean trial around a monitored, multi-part protocol, while keeping it blinded when the lab numbers themselves give the game away, is a serious scientific challenge.
7. It is simply an enormous amount of work
Put all of that together and you see the truth. Assembling investigators, securing funding, winning ethics approval, opening sites and running the thing for years is a colossal undertaking. It takes a rare combination of money, people, timing and sheer stubbornness to get a study like this across the line. None of those have aligned yet. That is why the shelf is empty, and it is why the absence of a big trial tells you far less than people assume.
Where that leaves us
It leaves patients in an awkward, lonely position.
On one side there are countless thousands of reports, built up over more than a decade, of this regimen helping people with cluster headache. I am not quoting a brochure. I read these accounts myself, almost weekly now, from people all over the world. On the other side there is no large trial to wave at a sceptic, and a patient who raises it with their GP often hits a wall.
I will be honest about how that makes me feel. It infuriates me. Because from where I stand, this molecule, for its potential against one of the most painful conditions a human can endure, is genuinely safe when it is respected. Safe when the regimen is followed. Safe when baseline bloods are done first. Safe when a doctor is willing, as my guest Professor Bruce Hollis put it to me, to step up and do this stuff.
But hang on. Is it actually safe?
This is the question that should come next, and I never want anyone to skip it.
High-dose Vitamin D3 is not harmless in the abstract. The real risk is raised calcium, and it shows up when the wrong dose meets the wrong person with no monitoring. That is exactly why the regimen is built around blood tests, not bravado. You establish a baseline for 25(OH)D, calcium and PTH before you start. You monitor. You adjust by the numbers, not by hope. If you want the plain-English version of how those three markers relate, I wrote it up in PTH, calcium and 25(OH)D, and the companion piece on the blood tests you need first.
The target serum level the regimen aims for is roughly 80 to 100 ng/mL. Do not be nonchalant about that number. Respect it, monitor it, and keep your calcium in range. But do not be frightened of it either, because it is not the wild outlier people assume. I have taken 10,000 IU a day for eleven years. I am not a statue of marble. My calcium homeostasis is normal and my condition is under control. One patient is not a trial, and I would never pretend otherwise. But it is the ground truth I actually live in.
What two of the people who know vitamin D best told me
Here is something I keep coming back to.
Over the years I have been lucky enough to interview, on camera, two of the most prominent vitamin D scientists alive. One of them helped identify the active hormonal form of vitamin D as a young researcher back in the 1970s. These are not fringe voices. They are among the people who built the field.
Both Michael Holick and Bruce Hollis told me, plainly, that they keep their own vitamin D level around 80 ng/mL. You can watch both conversations in full, and I would encourage you to, rather than take my summary of them on trust.
Sit with that for a moment. The target the regimen aims at for cluster headache is 80 to 100 ng/mL, and here are two of the scientists who understand this molecule better than almost anyone choosing to sit at the lower end of that same range for themselves. Do not take my word for any of this. Do your own diligence. But do not dismiss it out of hand either.
And Bruce Hollis said something to me that I will never forget. I am paraphrasing his spirit faithfully. Physicians need to have guts. If you have patients like this, you need to step up and do this stuff.
Why your doctor may look blank, and what that does and does not mean
So why the blank stare across the desk?
Part of it is the fifteen minute consult window, where there is no room to explore anything unfamiliar. Part of it is that many doctors were simply never trained in vitamin D beyond preventing rickets, and do not have a working grasp of the relationship between calcium, PTH and 25(OH)D that the regimen is built on. If they do not understand that relationship, high doses sound reckless, and caution is the reasonable default.
I can respect caution. What I cannot respect is dismissal without a second look. If a doctor makes you feel small for even asking about the Vitamin D3 regimen, and will not take a further look because they are rushed or uninterested, it is fair to ask a hard question. How much can you trust that same person to properly weigh the rest of your healthcare? The uncomfortable truth, from the looks and the messages I have collected over many years, is that the status quo is not shifting quickly. Many clinicians either do not know, or know a little and do not truly understand the biology.
In an ideal world your doctor orders the labs and walks the loading protocol with you. In many cases, including my own, you end up educating yourself so you can do it safely and knowledgeably. I will admit it plainly. My own doctor is fairly nonchalant about the regimen, and when it comes to interpreting my lab results I trust my own informed reading first. That is my ground truth, earned over eleven years.
Look beyond the one barrel
One more thing worth knowing. High-dose vitamin D is not some oddity invented for cluster headache. If you look beyond this one condition you will find high doses being explored for a range of conditions, from psoriasis to multiple sclerosis. The work of Dr Cicero Coimbra is one starting point for that wider picture. I mention it not as a recommendation for those conditions, which are outside what this site covers, but to make a simple point. The idea of using vitamin D at therapeutic, monitored doses is bigger than our small corner of it.
Where I stand
This is probably the most forceful thing I have written on this site, and I have thought hard about whether to soften it. I decided not to, because it is the truth as I have lived it.
I am not asking you to be reckless. I am asking the opposite. Be diligent. Get your baseline bloods. Monitor. Bring a willing clinician alongside you if you possibly can. Apply the same care to this that you should apply to any medication or treatment you choose for your condition or conditions. But do not let the absence of a big trial, or a blank look across a desk, convince you that there is nothing here worth understanding.
I continue to host this information out of respect for the work of Pete Batcheller, and because the people writing to me every week deserve somewhere careful and honest to start. Hate me for the tone if you must. I genuinely do not know what other choice I have but to keep the information here, approached cautiously, carefully, and with the diligence this subject demands.
If you are ready to understand the protocol itself properly, start with the full regimen guide, read the loading dose evidence, and look through the evidence hub. Then do what I keep asking. Your own diligence.
Leave a Comment